Study Purpose:
Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way. The goal of this research is to identify the characteristics that consistently restrict patients' ability to participate in or complete a trial in which they were initially interested. This data will be analyzed via a number of demographic lenses in order to find trends that could benefit future ALS sufferers.Study Status:
Not yet recruiting
Disease:
ALS , Amyotrophic Lateral Sclerosis
Study Type:
Observational
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Michael B Gill, Power Life Sciences Inc.
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Michael B Gill / https://www.withpower.com/contact-us@withpower.com / 415-900-4227
Study Sponsor:
Power Life Sciences Inc.
Estimated Enrollment:
500
Estimated Study Start Date:
07 / 01 / 2023
Estimated Study Completion Date:
07 / 01 / 2025
Posting Last Modified Date:
03 / 06 / 2023
Date Study Added to neals.org:
06 / 21 / 2022
Minimum Age:
18 Years
Maximum Age:
N/A
Inclusion Criteria:- Lives in the United States
- Is 18+ years old
- Participant has a diagnosis of Amyotrophic Lateral Sclerosis (ALS)
- Participant has enrolled in an interventional clinical for ALS (self-reported)
Exclusion Criteria
- Inability to perform regular electronic reporting
- Patient does not understand, sign, and return consent form
- No diagnosis of Amyotrophic Lateral Sclerosis (ALS) confirmed